Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Sponsor
Fondazione Italiana Linfomi - ETS
Study ID
NCT01009970
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    375 mg/m2 day 1
  • Cyclophosphamide — DRUG
    750 mg/m2 day 2
  • Vincristine — DRUG
    1,4 mg/m2 (max 2 mg) day 2
  • Prednisone — DRUG
    40 mg/m2 day 2-6
  • Doxorubicin — DRUG
    50 mg/m2 day 2

Study Details

This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.

Key Dates

Start date
May 31, 2010
Status verified
Oct 2011
Primary completion
May 31, 2011
Completion
May 31, 2012

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    R-COMP

Primary Outcome Measure

Feasibility of R-COMP in cardiopathic patients [ Time Frame: 2 years ]

Central Contacts

Related Studies